Join to View Full Profile
530 E 74th StNew York, NY 10021
Phone+1 212-639-2000
Dr. Chin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kuo-Kai Chin is an internal medicine specialist with subspecialties in hematology and oncology, based in New York, NY. After completing his medical degree at Stanford University School of Medicine in 2019, he completed an internal medicine residency at Brigham and Women's Hospital and is currently pursuing a fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. His research has been published in several peer-reviewed journals, including Leukemia & Lymphoma and the Clinical Journal of the American Society of Nephrology, with notable citations in the field of chronic graft-versus-host disease and recurrent FSGS after kidney transplantation.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2022 - 2025
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2019 - 2022
Stanford University School of MedicineClass of 2019
Certifications & Licensure
NJ State Medical License 2025 - 2027
NY State Medical License 2022 - 2025
MA State Medical License 2019 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.Meira Yisraeli Salman, Alexander R Terry, Andriy Derkach, David Nemirovsky, Kuo-Kai Chin
Blood Advances. 2025-07-08 - Barriers to Chimeric Antigen Receptor T-Cell Therapy.Yannis K Valtis, Kuo-Kai Chin, David Nemirovsky, Sean M Devlin, Meira Yisraeli Salman
JAMA Oncology. 2025-05-15 - 2 citationsIbrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.Joseph Pidala, Jongphil Kim, Denise Kalos, Corey Cutler, Zachariah DeFilipp
Blood Advances. 2025-03-11
Professional Memberships
- Gold Humanism Honor SocietyMember
Other Languages
- Chinese (Mandarin), Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
